La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

AroCell Salute del bilancio

Salute finanziaria criteri di controllo 5/6

AroCell ha un patrimonio netto totale di SEK153.1M e un debito totale di SEK0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente SEK164.5M e SEK11.4M.

Informazioni chiave

Rapporto debito/patrimonio netto

SEK 0

Debito

Indice di copertura degli interessi	n/a
Contanti	SEK 48.71m
Patrimonio netto	SEK 140.05m
Totale passività	SEK 12.83m
Totale attività	SEK 152.88m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

Apr 20

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Feb 27

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Nov 07

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

Aug 10

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

Apr 18

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Jan 03

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK66.0M ) di AROC superano le sue passività a breve termine ( SEK11.4M ).

Passività a lungo termine: Le attività a breve termine di AROC ( SEK65.3M ) non coprono le sue passività a lungo termine ( SEK-1,000.0 ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: AROC è esente da debiti.

Riduzione del debito: AROC non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: AROC ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: AROC ha una liquidità sufficiente per più di 3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 3.3 % ogni anno

AroCell Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

Recent updates

Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)

New minor risk - Share price stability

First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)

AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024

AroCell AB (publ), Annual General Meeting, May 22, 2024

Is Now The Time To Look At Buying AroCell AB (publ) (STO:AROC)?

AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025

Now 22% undervalued after recent price drop

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of AroCell AB (publ) (STO:AROC)

Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)

AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

AroCell AB (publ) Announces Chief Financial Officer Changes

Consensus revenue estimates fall by 12%

At kr0.45, Is AroCell AB (publ) (STO:AROC) Worth Looking At Closely?

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)

New major risk - Market cap size

AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian Cancer

New major risk - Market cap size

Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)

First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)

Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)

Price target decreased to kr2.30

High number of new and inexperienced directors

Consensus revenue estimates increase by 17%

Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)

Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)

AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

AroCell Announced UBC® Rapid is Now Verified for Use on New Instrument

High number of new and inexperienced directors

Chief Executive Officer recently bought kr221k worth of stock

AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African Market

First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)

Price target decreased to kr2.00

High number of new directors

AroCell AB (publ) Announces CFO Changes

Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)

High number of new directors

AroCell AB (publ), Annual General Meeting, May 24, 2022

Head of Operations recently bought kr81k worth of stock

We Think AroCell (STO:AROC) Can Afford To Drive Business Growth

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)

AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.

Chief Commercial Officer has left the company

AroCell (STO:AROC) Is In A Good Position To Deliver On Growth Plans

New 90-day high: kr3.41

Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)

AroCell AB (publ), Annual General Meeting, May 06, 2021

Head of Operations recently bought kr91k worth of stock

Head of Operations recently bought kr91k worth of stock

AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical Officer

AroCell AB (publ) Appoints Anders Hultman as CEO

We're Hopeful That AroCell (STO:AROC) Will Use Its Cash Wisely

New 90-day low: kr2.43

Earnings released

New 90-day high - kr3.64

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane